Macquarie Group
DOVA

Macquarie Group’s Dova Pharmaceuticals, Inc. Common Stock DOVA Stock Holding History

Macquarie Group’s Portfolio DOVA Stock Details DOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,100
Closed -$32K – 2502
2017
Q4 		$32K Buy
+1,100
New +$30.1K ﹤0.01% 2123

Other funds holding DOVA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
PC
Pier Capital Stamford, Connecticut $606M AUM 63.41% 1-Year Est. Return

Macquarie Group's DOVA Position: Q1 2018 in Review

Macquarie Group sold out of Dova Pharmaceuticals, Inc. Common Stock (DOVA) in Q1 2018, closing a stake of 1,100 shares — an estimated $32K sold.

Macquarie Group first reported a position in DOVA in Q4 2017 and held it in 1 quarter. The position peaked at $32K in Q4 2017. 55 funds tracked by Wall St. Rank hold DOVA as of Q1 2018.

  • Macquarie Group reported no remaining Dova Pharmaceuticals, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Macquarie Group sold 1,100 Dova Pharmaceuticals, Inc. Common Stock shares in Q1 2018, an estimated $32K.
  • Macquarie Group first reported a position in Dova Pharmaceuticals, Inc. Common Stock in Q4 2017 and held it in 1 quarter.
  • Macquarie Group's Dova Pharmaceuticals, Inc. Common Stock position peaked at $32K in Q4 2017.
  • 55 funds tracked by Wall St. Rank held Dova Pharmaceuticals, Inc. Common Stock as of Q1 2018.

Based on Macquarie Group's 13F filing for Q1 2018, filed 11 May 2018.